Pfizer’s CMO Unit Expands Fill-Finish Services

From DCAT Value Chain Insights (VCI)

By Supplier News posted 02-22-2017 12:36


Pfizer CentreOne, a contract manufacturing organization (CMO) within Pfizer, has expanded its fill-finish services at its Kalamazoo, Michigan site. The facility now provides vial-filling of sterile suspensions along with vial-filling of small molecules and biologics.

Pfizer CentreOne’s vial-filling services at the Kalamazoo site encompass small molecules and biologics, sterile suspensions, potent and controlled substances, aqueous and oil-based formulations, lyophilization, vials in 1-mL to 100-mL sizes, bulk formulation ranging from less than 1 liter to 1,600 liters, and technical transfer.

The CMO was formed by the union of Pfizer CentreSource and Hospira One 2 One, a sterile-injectables CMO, following Pfizer’s $17-billion acquisition of Hospira in 2015. Pfizer CentreOne focuses on active pharmaceutical ingredient synthesis, sterile injectables fill-finish, and highly potent solids.

Source: Pfizer CentreOne 


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription